This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
by Sundeep Ganoria
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
by Zacks Equity Research
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
BIIBPositive Net Change LLYPositive Net Change ADPTPositive Net Change AKROPositive Net Change
pharmaceuticals
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
by Zacks Equity Research
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
CRMDPositive Net Change CDTXPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
by Ekta Bagri
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
by Aparajita Dutta
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
AZNPositive Net Change PFEPositive Net Change LLYPositive Net Change IHEPositive Net Change XPHPositive Net Change PPHPositive Net Change FTXHPositive Net Change
medical pharmaceuticals
Best Value Stock to Buy for September 26th
by Zacks Equity Research
BAYRY, CARS and MRX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 26, 2025.
BAYRYPositive Net Change MRXPositive Net Change CARSPositive Net Change
finance pharmaceuticals retail
Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI
by Shaun Pruitt
Two medical sector stocks are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list in Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI).
MASIPositive Net Change COLLNegative Net Change ALCPositive Net Change SONVYPositive Net Change
earnings investing medical medical-devices pharmaceuticals
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
by Ekta Bagri
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
AZNPositive Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
by Kinjel Shah
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.
AZNPositive Net Change JNJPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
by Zacks Equity Research
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
AZNPositive Net Change RHHBYNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
by Zacks Equity Research
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
CRMDPositive Net Change QUREPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs gene-therapy genomics medical pharmaceuticals
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
by Zacks Equity Research
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
CRMDPositive Net Change ACADNegative Net Change SLNOPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
by Zacks Equity Research
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
HALONegative Net Change ANIPNegative Net Change HRMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
by Sundeep Ganoria
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
by Kinjel Shah
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
pharmaceuticals
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
by Zacks Equity Research
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
BMYPositive Net Change CRMDPositive Net Change REPLPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
BMYPositive Net Change HALONegative Net Change ANIPNegative Net Change BNTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
by Shaun Pruitt
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
PFEPositive Net Change MTSRNegative Net Change NVONegative Net Change LLYPositive Net Change
biotechnology dividends earnings investing medical pharmaceuticals vaccines
Top Analyst Reports for Apple, Eli Lilly & Chevron
by Mark Vickery
Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.
AAPLNegative Net Change CVXNegative Net Change CEGPositive Net Change LLYPositive Net Change STXNegative Net Change CORPositive Net Change MCEMPositive Net Change
computers construction oil-energy pharmaceuticals
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
by Zacks Equity Research
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
AZNPositive Net Change GSKPositive Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs medical pharmaceuticals
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
by Kinjel Shah
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change MTSRNegative Net Change
pharmaceuticals
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
by Ahan Chakraborty
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change MIRMNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
by Ekta Bagri
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
BDTXPositive Net Change CGEMNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector
HALONegative Net Change ANIPNegative Net Change KNSAPositive Net Change TWSTPositive Net Change AKROPositive Net Change
biotechnology biotechs medical pharmaceuticals